The body breaks down the endocannabinoid anandamide through multiple enzyme pathways with distinct products
A review detailed how cytochrome P450 enzymes metabolize anandamide into structurally diverse lipids, some of which activate cannabinoid receptors, complicating the development of FAAH inhibitor drugs.
Quick Facts
What This Study Found
The review focused on an underappreciated aspect of endocannabinoid biology: the oxidation of anandamide by cytochrome P450 enzymes.
While FAAH is the primary enzyme that breaks down anandamide, several P450 enzymes (CYP3A4, CYP4F2, CYP4X1, and the highly variable CYP2D6) also metabolize anandamide into structurally diverse lipid products.
Critically, one P450-derived epoxide of anandamide was found to be a potent agonist at CB2 receptors. This meant that blocking FAAH alone (the approach being developed for pain treatment) might not fully control endocannabinoid signaling because alternative metabolic pathways would still produce active compounds.
The genetic variability in CYP2D6 across individuals could lead to different responses to endocannabinoid-targeting drugs.
Key Numbers
Four P450 enzymes identified: CYP3A4, CYP4F2, CYP4X1, CYP2D6. One P450-derived epoxide was a potent CB2 agonist. CYP2D6 is highly polymorphic across populations.
How They Did This
Comprehensive review published in Pharmacological Reviews examining the cytochrome P450-mediated oxidation pathways of anandamide, their physiological significance, and implications for drug development.
Why This Research Matters
Understanding that multiple enzyme systems process anandamide into bioactive products was essential for developing effective endocannabinoid-targeting drugs, particularly FAAH inhibitors being developed for pain and inflammation.
The Bigger Picture
This research highlighted the complexity of the endocannabinoid system beyond simple production and degradation, with multiple metabolic pathways generating diverse bioactive lipids that could influence therapeutic outcomes.
What This Study Doesn't Tell Us
Much of the evidence came from in vitro enzyme studies. The physiological relevance of P450-mediated anandamide metabolism in vivo required further investigation. The clinical implications were still theoretical.
Questions This Raises
- ?How do P450-mediated anandamide metabolites contribute to endocannabinoid signaling in vivo?
- ?Should FAAH inhibitor drug development account for these alternative metabolic pathways?
Trust & Context
- Key Stat:
- A P450-derived anandamide metabolite is a potent CB2 receptor agonist
- Evidence Grade:
- Comprehensive review in a leading pharmacology journal synthesizing biochemical evidence across multiple enzyme pathways.
- Study Age:
- Published in 2010. FAAH inhibitor development has continued with these complexities in mind.
- Original Title:
- Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
- Published In:
- Pharmacological reviews, 62(1), 136-54 (2010)
- Authors:
- Snider, Natasha T, Walker, Vyvyca J, Hollenberg, Paul F
- Database ID:
- RTHC-00454
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this have to do with cannabis?
Anandamide is the body's own cannabinoid. Understanding how it is processed and broken down is essential for developing drugs that target the same system as cannabis, such as pain medications that boost endocannabinoid levels.
Why does genetic variation in CYP2D6 matter?
CYP2D6 varies widely between individuals and populations. Since this enzyme processes anandamide into bioactive products, people with different CYP2D6 variants may have different endocannabinoid signaling and different responses to cannabis or endocannabinoid-targeting drugs.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- thc-and-antibiotics-safe-cannabis-while-on
- thc-and-caffeine-most-common-drug-combo
- thc-and-diabetes-medication-blood-sugar
Cite This Study
https://rethinkthc.com/research/RTHC-00454APA
Snider, Natasha T; Walker, Vyvyca J; Hollenberg, Paul F. (2010). Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.. Pharmacological reviews, 62(1), 136-54. https://doi.org/10.1124/pr.109.001081
MLA
Snider, Natasha T, et al. "Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.." Pharmacological reviews, 2010. https://doi.org/10.1124/pr.109.001081
RethinkTHC
RethinkTHC Research Database. "Oxidation of the endogenous cannabinoid arachidonoyl ethanol..." RTHC-00454. Retrieved from https://rethinkthc.com/research/snider-2010-oxidation-of-the-endogenous
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.